RAP - The Main Game, page-1601

Seasonal variations have affected the incidence rate of key diseases observed during our SMARTCOUGH-C study and we need to adapt accordingly,” said Tony Keating, CEO and Managing Director of ResApp. “By increasing the total number of patients recruited we will improve the statistical power of our results and incorporate a wider range of respiratory diseases. This in turn will strengthen our FDA submission and support our goal of providing a complete differential diagnosis tool for respiratory disease.”

The company advises that it remains on-track to complete enrolment, release top- line results and submit its de novo submission to the FDA in the first half of CY2017.


I've got total faith in Tony Keating's ability to drive this company....

I love this bit...."incorporate a wider range of respiratory diseases"

Tick tock...